Synmosa Biopharma Corp(TW:4114)
NT$27.75-0.10 (-0.36%)
TW:4114
Synmosa Biopharma Corp financials statements
NT$27.75
At close:-0.10 (-0.36%)
Synmosa Biopharma Corp (4114) Ratios
Synmosa Biopharma Corp Ratios
TW:4114's free cash flow for Q2 2026 was NT$-144.57M. For the 2026 fiscal year, TW:4114's free cash flow was decreased by NT$-50.64M and operating cash flow was NT$-93.93M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.95 | 2.42 | 2.14 | 1.73 | 1.64 |
| Quick Ratio | 1.98 | 1.60 | 1.36 | 1.16 | 1.02 |
| Cash Ratio | 0.84 | 0.57 | 0.43 | 0.47 | 0.46 |
| Solvency Ratio | 0.30 | 0.26 | 0.26 | 0.25 | 0.14 |
| Operating Cash Flow Ratio | 0.18 | 0.38 | 0.24 | 0.27 | 0.24 |
| Short-Term Operating Cash Flow Coverage | 0.45 | 1.04 | 0.54 | 0.54 | 0.39 |
| Net Current Asset Value | NT$ 2.78B | NT$ 1.11B | NT$ 911.64M | NT$ -545.33M | NT$ -1.12B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.18 | 0.21 | 0.21 | 0.30 | 0.34 |
| Debt-to-Equity Ratio | 0.29 | 0.35 | 0.36 | 0.63 | 0.74 |
| Debt-to-Capital Ratio | 0.22 | 0.26 | 0.27 | 0.39 | 0.42 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.19 | 0.17 | 0.29 | 0.33 |
| Financial Leverage Ratio | 1.60 | 1.71 | 1.75 | 2.11 | 2.19 |
| Debt Service Coverage Ratio | 0.96 | 1.08 | 0.80 | 0.81 | 0.38 |
| Interest Coverage Ratio | 12.54 | 12.72 | 9.14 | 13.23 | 4.00 |
| Debt to Market Cap | 0.22 | 0.20 | 0.20 | 0.28 | 0.64 |
| Interest Debt Per Share | 6.92 | 6.17 | 6.15 | 9.65 | 9.72 |
| Net Debt to EBITDA | 0.56 | 1.29 | 1.51 | 2.07 | 5.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.02% | 43.26% | 41.24% | 41.64% | 39.73% |
| EBIT Margin | 12.58% | 12.92% | 13.01% | 17.89% | 6.36% |
| EBITDA Margin | 18.12% | 19.09% | 19.62% | 25.19% | 15.70% |
| Operating Profit Margin | 12.58% | 13.32% | 11.96% | 17.96% | 6.42% |
| Pretax Profit Margin | 12.92% | 11.88% | 11.70% | 16.53% | 4.76% |
| Net Profit Margin | 13.28% | 12.34% | 11.57% | 18.22% | 9.39% |
| Continuous Operations Profit Margin | 9.99% | 8.45% | 7.88% | 14.49% | 4.10% |
| Net Income Per EBT | 102.78% | 103.89% | 98.88% | 110.22% | 197.46% |
| EBT Per EBIT | 102.72% | 89.17% | 97.86% | 92.01% | 74.10% |
| Return on Assets (ROA) | 5.88% | 5.56% | 5.07% | 7.13% | 2.95% |
| Return on Equity (ROE) | 9.38% | 9.50% | 8.87% | 15.04% | 6.46% |
| Return on Capital Employed (ROCE) | 6.64% | 7.22% | 6.40% | 8.87% | 2.46% |
| Return on Invested Capital (ROIC) | 4.75% | 4.78% | 3.91% | 6.68% | 1.63% |
| Return on Tangible Assets | 6.06% | 5.81% | 5.33% | 7.51% | 3.10% |
| Earnings Yield | 7.35% | 5.61% | 4.94% | 6.69% | 5.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.46 | 4.42 | 4.41 | 3.83 | 3.99 |
| Payables Turnover | 6.54 | 6.72 | 7.19 | 5.96 | 7.84 |
| Inventory Turnover | 1.67 | 1.85 | 1.83 | 1.96 | 1.66 |
| Fixed Asset Turnover | 1.14 | 0.99 | 0.93 | 0.78 | 0.57 |
| Asset Turnover | 0.44 | 0.45 | 0.44 | 0.39 | 0.31 |
| Working Capital Turnover Ratio | 1.68 | 2.07 | 2.50 | 3.03 | 2.46 |
| Cash Conversion Cycle | 245.22 | 225.98 | 231.52 | 220.10 | 264.82 |
| Days of Sales Outstanding | 81.87 | 82.58 | 82.82 | 95.37 | 91.40 |
| Days of Inventory Outstanding | 219.18 | 197.71 | 199.48 | 186.00 | 219.96 |
| Days of Payables Outstanding | 55.83 | 54.30 | 50.79 | 61.27 | 46.54 |
| Operating Cycle | 301.05 | 280.28 | 282.30 | 281.37 | 311.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.10 | 1.85 | 1.26 | 1.77 | 1.26 |
| Free Cash Flow Per Share | 0.35 | 1.21 | 0.59 | 1.25 | 0.86 |
| Dividend Paid and CapEx Coverage Ratio | 0.74 | 1.57 | 1.10 | 1.89 | 2.05 |
| Capital Expenditure Coverage Ratio | 1.46 | 2.89 | 1.90 | 3.42 | 3.20 |
| Operating Cash Flow Coverage Ratio | 0.16 | 0.31 | 0.21 | 0.19 | 0.13 |
| Operating Cash Flow to Sales Ratio | 0.07 | 0.14 | 0.10 | 0.14 | 0.14 |
| Free Cash Flow Yield | 1.17% | 4.19% | 2.01% | 3.73% | 5.85% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.07 | 19.65 | 20.25 | 14.94 | 17.61 |
| Price-to-Sales (P/S) Ratio | 1.81 | 2.20 | 2.34 | 2.72 | 1.65 |
| Price-to-Book (P/B) Ratio | 1.28 | 1.69 | 1.80 | 2.25 | 1.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 85.68 | 23.89 | 49.76 | 26.80 | 17.10 |
| Price-to-Operating Cash Flow Ratio | 27.16 | 15.64 | 23.54 | 18.96 | 11.76 |
| Price-to-Earnings Growth (PEG) Ratio | 1.40 | 28.69 | -0.58 | 0.09 | -0.30 |
| Enterprise Value Multiple | 10.52 | 12.82 | 13.45 | 12.88 | 15.64 |
| Enterprise Value | 11.80B | 13.57B | 13.57B | 14.24B | 7.94B |
| EV to EBITDA | 10.52 | 12.82 | 13.45 | 12.88 | 15.64 |
| EV to Sales | 1.91 | 2.45 | 2.64 | 3.25 | 2.46 |
| EV to Free Cash Flow | 90.47 | 26.57 | 56.04 | 31.92 | 25.40 |
| EV to Operating Cash Flow | 28.67 | 17.39 | 26.51 | 22.59 | 17.46 |
| Tangible Book Value Per Share | 25.94 | 18.66 | 18.51 | 17.11 | 15.47 |
| Shareholders’ Equity Per Share | 23.52 | 17.06 | 16.46 | 14.94 | 13.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.29 | 0.33 | 0.15 | 0.25 |
| Revenue Per Share | 16.61 | 13.13 | 12.61 | 12.34 | 8.95 |
| Net Income Per Share | 2.21 | 1.62 | 1.46 | 2.25 | 0.84 |
| Tax Burden | 1.03 | 1.04 | 0.99 | 1.10 | 1.97 |
| Interest Burden | 1.03 | 0.92 | 0.90 | 0.92 | 0.75 |
| Research & Development to Revenue | 0.06 | 0.05 | 0.04 | 0.05 | 0.07 |
| SG&A to Revenue | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 |
| Stock-Based Compensation to Revenue | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 |
| Income Quality | 0.51 | 1.18 | 0.86 | 0.87 | 2.96 |
Currency in TWD
